{"filings":[{"id":2162077,"accession_number":"0001437749-26-026769","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2026-08-10T20:03:03+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q1 revenue +1.0%; AOI up 19.5%; net income down on FX","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $60.1M, up 1.0% YoY; core organic growth 0.4%, first positive quarter.","Operating income up 129% to $7.0M; non-GAAP AOI ex unusual items up 19.5% to $15.4M.","Net income down 40.3% to $2.8M ($0.49 diluted) on FX losses vs prior-year gains.","Repaid $8.7M debt; total net leverage ratio 1.85, below 2.0 target.","CEO Siddhartha Kadia (joined ~100 days ago) to give full-year guidance in November."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1970277,"accession_number":"0000724004-26-000082","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2026-07-30T21:18:47+00:00","items":["5.05","9.01"],"status":"ready","headline":"Mesa Laboratories amends Code of Ethics and Business Conduct","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved amended Code on July 30, 2026, effective immediately.","Updates include revisions to external communications and social media policies.","Other clarifying, administrative, compliance and procedural updates made.","Amended Code filed as Exhibit 14.1 to this Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1059237,"accession_number":"0000724004-26-000056","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2026-06-15T21:29:57+00:00","items":["5.02","9.01"],"status":"ready","headline":"Mesa Labs appoints Lyndsey Crennen as Chief Accounting Officer; base salary $325,000","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective June 11, 2026; Crennen previously Corporate Controller since 2022.","Base salary of $325,000; eligible for annual cash bonus at 40% target ($130,000) and long-term incentive target $300,000.","Employment agreement includes customary severance; to be entered by June 26, 2026.","No family relationships or related party transactions with existing directors or officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":677761,"accession_number":"0000724004-26-000039","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2026-05-27T12:00:13+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q4 revenue up 2.6% but net loss $4.1M; BPD revenue falls 29.9% on export controls","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $63.7M (+2.6% YoY); net loss $4.1M ($0.75 loss per share) vs prior year loss of $7.1M.","Non-GAAP AOI margin 28.7% (vs 19.7% last year) driven by SDC backlog clearance and cost actions.","BPD division revenue declined 29.9% due to export controls delaying Peptide system shipments; BPD core organic -31.6%.","SDC organic growth 17.7% aided by ~$2M backlog reduction; full-year SDC organic 8.7%.","Repaid $14.7M debt in Q4; net leverage ratio 2.11; CFO expects overall core organic growth positive in Q1 FY27."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114054,"accession_number":"0000724004-26-000030","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Gary Owens to depart by April 13; remains non-executive through June 22","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Owens steps down as President and CEO effective ~April 13, 2026; stays in non-executive role until June 22, 2026.","Owens resigned from the Board on March 20, 2026; no disagreement with Company cited.","Transition Agreement provides severance of 1x base salary ($815K) plus 1x target bonus ($896.5K), prorated FY27 bonus, and accelerated vesting of certain equity awards.","Owens eligible for up to $10,000 legal fee reimbursement; severance conditioned on signing a release of claims.","No successor CEO has been named; Board is managing the transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114053,"accession_number":"0000724004-26-000020","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Mesa Labs appoints Siddhartha Kadia as CEO to succeed Gary Owens effective April 13, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gary Owens departs as President and CEO effective April 12, 2026; separation not due to any disagreement.","Dr. Siddhartha Kadia appointed as President and CEO and to the Board, effective April 13, 2026.","Kadia previously CEO of Calibre Scientific, PhenomeX/Berkeley Lights, and EAG Laboratories; over 20 years in life sciences.","Compensation: $850k base salary, annual bonus target at least 100% of base, initial equity awards of $3M RSUs and $3M target PSUs.","Board conducted comprehensive external search; Kadia's appointment part of long-term leadership strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114052,"accession_number":"0000724004-26-000015","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q3 revenue up 3.6% to $65.1M; net income surges 317% to $3.63M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $65.1M, +3.6% YoY; core organic growth 1.2%.","Operating income $7.98M, +38%; AOI $17.07M, +15.4%.","Net income $3.63M, diluted EPS $0.65 vs $0.16 YoY.","Repaid $8.7M debt; total net leverage ratio improved to 2.62.","BPD division led with 17.5% organic growth; CG China revenue down 57%."],"consensus_eps_estimate":null,"consensus_eps_actual":1.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":185406000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130442,"accession_number":"0000724004-25-000012","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs 2Q26 revenue up 5%, net income down 27.8% on tariffs and China headwinds","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $60.7M, +5.0% YoY; core organic growth 3.7%.","Net income $2.5M ($0.45 diluted EPS), down 27.8% from 2Q25.","Non-GAAP AOI excluding unusual items $15.2M, +6.1%; margin 25.1% vs 24.8%.","Clinical Genomics core organic -3.6%: China -58%; outside China +16.2%.","Annualized cost reductions of $3.2M; net savings $2.3M after reinvestment. Tariffs 70 bps of revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":120280000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146995,"accession_number":"0001437749-25-027659","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Mesa Laboratories holds 2025 annual meeting; shareholders elect all seven director nominees and approve amendments","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 7 director nominees elected with >90% support; vote totals range from 4.69M to 4.85M for.","Baker Tilly ratified as independent auditor for FY2026 with 5,200,789 for (99.97% of votes cast).","Non-binding say-on-pay approved: 4,476,544 for (91.6% of votes cast excluding broker non-votes).","Amendment to 2021 Equity Incentive Plan approved: 4,601,685 for (94.2% of votes cast).","Board committee chairs appointed: Audit (Tripeny), Compensation (Capone), Nominating (Alltoft)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146994,"accession_number":"0001437749-25-027225","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["2.03","9.01"],"status":"ready","headline":"Mesa Laboratories draws $97M under credit facility to repay convertible notes due August 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Drew $97M under existing Credit Agreement to settle $97.5M of 1.375% Convertible Senior Notes maturing August 2025; total outstanding under credit facility now $108M.","Interest rate on credit facility currently 7.18%, expected to decrease with Fed rate reductions and an additional 25 bps when net leverage ratio falls below 3.0x (expected by Q3 FY2026).","Total net leverage ratio was 3.16 as of June 30, 2025; expected principal payments of ~$20M in Q2–Q4 FY2026 with higher payments in FY2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146993,"accession_number":"0001437749-25-024714","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Laboratories Reports First Quarter Fiscal 2026 Results","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues increased 2.4% to $59,543,000 for the quarter ended June 30, 2025.","Operating income decreased 45.1% to $3,064,000, impacted by FX and stock-based compensation.","Clinical Genomics division revenue fell 10.7% core organic as China revenues contracted 69%.","About $1.5M of expected Biopharmaceutical Development revenues shifted from Q1 to Q2 due to tariff surcharges.","Non-GAAP adjusted operating income (excluding unusual items) was $12,902, down 15.9% year-over-year."],"consensus_eps_estimate":null,"consensus_eps_actual":0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":59543000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165505,"accession_number":"0001437749-25-019696","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Mesa Labs auditor changes from Moss Adams to Baker Tilly after merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Moss Adams merged with Baker Tilly US, LLP effective June 3, 2025; Baker Tilly appointed as successor independent auditor.","No disagreements or reportable events with Moss Adams during fiscal 2025 or subsequent interim period.","Moss Adams' audit reports on FY2025 consolidated financials and internal controls were unqualified.","Audit Committee approved appointment of Baker Tilly; no prior consultations with Baker Tilly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165504,"accession_number":"0001437749-25-018585","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q4 revenue up 5.5% but net loss widens to $7.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $62.1M, up 5.5% YoY; core organic growth 6.3%.","GAAP net loss $7.1M ($1.31 diluted EPS) vs loss $3.6M in prior-year quarter.","Adjusted operating income excluding unusual items $12.3M, down 18% YoY.","Full fiscal year revenue $241M, up 11.5%; core organic growth 5.0%.","SDC division core organic growth 10.3%; CG division continued decline in China."],"consensus_eps_estimate":0.2822,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":240978000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183150,"accession_number":"0001437749-25-002661","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q3 revenue up 17.5% to $62.8M; core organic growth 13.2%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $62.8M (+17.5% YoY); non-GAAP core organic revenue +13.2%.","GAAP net loss $(1.68M) ($0.31 diluted); non-GAAP AOI ex unusual items $14.79M (+13.3%).","All four divisions grew: BPD +31.3% core organic, CS +18.9%, SDC +8.2%, CG +1.9% (3rd consecutive sequential rise).","Repaid $9.4M debt in Q3; net leverage ratio 3.20x; targeting below 3.0x by Q2 2026.","GKE acquisition contributed 4.9% inorganic growth and exceeded first-year expectations."],"consensus_eps_estimate":0.1632,"consensus_eps_actual":0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":178843000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199725,"accession_number":"0001437749-24-033744","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q2 revenue $57.8M (+8.8% YoY); core organic revs -2.8%; AOI margin 24.8%; net debt reduced by $7.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $57.8M (+8.8% YoY); net income $3.4M ($0.63 diluted EPS) vs. prior year loss.","Non-GAAP AOI ex-unusual items $14.4M, margin 24.8% (up 210 bps); core organic revs declined 2.8%.","BPD division core organic growth 27.9% (strong capital equipment); CG declined 26.5% (China/LDT headwinds).","Repaid $7.4M debt in Q2; Net Leverage Ratio improved to 3.26, targeting below 3.0x.","GKE acquisition (closed late 2023) contributed 11% revenue growth, ahead of initial expectations."],"consensus_eps_estimate":0.4454,"consensus_eps_actual":1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":116003000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215744,"accession_number":"0001437749-24-028898","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Mesa Labs names Moss Adams as new auditor, replacing RSM US LLP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee appointed Moss Adams as independent auditor for FY ending March 31, 2025, dismissing RSM effective immediately.","No disagreements with RSM or former auditor Plante & Moran on accounting principles or audit scope.","RSM's audit reports for FY 2024 and Plante & Moran's for FY 2023 were unqualified, with no adverse opinions.","Previously reported material weaknesses in internal control over financial reporting were noted in 8-K disclosures.","RSM furnished a letter agreeing with the Company's statements, filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215743,"accession_number":"0001437749-24-028148","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Mesa Laboratories shareholders elect all 7 director nominees, ratify RSM US LLP as auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected: John Sullivan, Gary Owens, Shannon Hall, Jenny Alltoft, Shiraz Ladiwala, Tony Tripeny, Mark Capone.","RSM US LLP ratified as independent auditor for FY ending March 31, 2025 with 4,992,593 votes for.","Non-binding advisory vote on executive compensation approved with 4,581,083 votes for.","Annual meeting held August 30, 2024; 5,096,365 of 5,409,163 eligible shares represented.","Broker non-votes of 255,479 on director elections and say-on-pay; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215742,"accession_number":"0001437749-24-024570","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q1 revenue $58.2M (+14.9%), EPS $0.62; operating income up 940%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $58.2M (+14.9% YoY); net income $3.4M (+717%); diluted EPS $0.62.","Non-GAAP core organic revenue growth 3.0%; AOI excl. unusual items $15.3M (+47%).","Divisions: BPD core organic growth 23.5%; CG declined 14.3% (China/US headwinds).","Repaid $9.4M debt; net leverage ratio reduced to 3.41 (target <3.0x).","GKE acquisition contributing above expectations; non-cash inventory step-up charges to end by 2Q25."],"consensus_eps_estimate":null,"consensus_eps_actual":0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":58170000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235148,"accession_number":"0001437749-24-019257","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q4 net loss of $254.6M on $274.5M impairment; core organic revenues down 3.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $58.9M (+6% YoY); core organic revenue declined 3.5% due to headwinds in Clinical Genomics and Biopharma.","Full-year operating loss of $272.1M includes $274.5M non-cash impairment of goodwill and long-lived assets.","Non-GAAP AOI excluding unusual items rose 26.3% in Q4 to $14.9M; full-year AOI +0.7% to $50.5M.","Clinical Genomics division restructured with 17 position eliminations, expects ~$3M annual savings.","SDC division grew 37.3% (including GKE China acquisition); BPD and CG declined organically."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235147,"accession_number":"0001437749-24-011307","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2024-04-08T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Mesa Labs amends credit facility, adds $75M term loan; repurchases $75M of 2025 convertible notes at discount","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended credit agreement: $75M term loan + $125M revolver, matures April 2029, interest at SOFR + 1.5%-3.5%.","Repurchased $75M aggregate principal of 1.375% convertible notes due 2025 for $71.25M cash; closing expected April 11, 2024.","After repurchase, $97.5M of 2025 notes remain outstanding; total credit facility debt $125.5M ($75M term loan + $50.5M revolver).","CFO aims to reduce total net leverage ratio to below 3.0x over next 18 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235146,"accession_number":"0001437749-24-010537","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["2.06","9.01"],"status":"ready","headline":"Mesa Labs expects $271M non-cash impairment charge for FY2024, impacting two divisions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-cash impairment of ~$271M for Clinical Genomics and Biopharmaceutical Development divisions in Q4 FY2024.","Goodwill impairment of ~$123M ($98M Clinical Genomics, $25M Biopharm Dev) and intangible asset impairment of ~$148M ($114M and $34M).","Driven by restructuring (eliminated 17 positions), loss of Sema4 as customer, macro uncertainty, and higher discount rates.","Non-cash charge does not affect cash flows from operations; final amounts subject to change upon 10-K filing.","Management cites new strategies, downward revenue revisions, and elevated interest rates as key factors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252965,"accession_number":"0001437749-24-003052","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q3 revenue down 1.5%; operating loss of $67K; core organic revenue declines 9%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $53.5M, down 1.5% YoY; core organic revenue declined 9%.","Operating loss of $67K vs income $3.2M prior year; net income $2.1M up 369% on unusual items.","Non-GAAP adjusted operating income excl. unusual items $12.0M, down 6.8% YoY but up 7.3% sequentially.","Clinical Genomics down 19% on China anti-corruption; Biopharm capital constrained but consumables +16.5%.","Calibration Solutions revenue +12.9%, gross margin +600 bps; GKE acquisition added $3.8M revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":157283000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252964,"accession_number":"0001437749-24-000821","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Mesa Laboratories appoints Mark Capone to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 6 to 7 members; Capone appointed effective Jan 5, 2024.","Capone most recently served as CEO/President of Myriad Genetics; also 17 yrs at Eli Lilly.","Appointed to Audit Committee, replacing Shiraz Ladiwala.","Capone determined independent under Nasdaq and SEC rules.","No related party transactions with Mesa reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270450,"accession_number":"0001437749-23-030284","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q2 revenue down 9.5% to $53.2M, net loss of $1.23M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Operating income turned negative at $(60), down 101.5% vs prior year.","Non-GAAP adj. operating income ex unusual items fell 29.1% to $11.2M.","Clinical Genomics down 15.7% organic on Sema4 loss ($8.2M annual headwind).","Biopharm Development revenues fell 24.4% organic, consumables up 4.7%.","Cost actions expected to save ~$2M annually starting in Q3; GKE acquisition closed Oct 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":103810000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270449,"accession_number":"0001437749-23-028494","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2023-10-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Mesa Labs completes acquisition of GKE for €85M; expects €19-20M revenue add","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired GKE sterilization indicators business, SAL GmbH, and agreed to buy GKE China for €85M total.","Financed with $65M from credit facility and $12.6M cash; GKE China close expected in Q3 FY2024.","First 12 months of complete ownership expected to add €19-20M revenue with mid-single-digit organic growth.","Adjusted operating income margin expected to approach 37%-40% for the first 12 months.","Combined SDC division has over 200 distribution partners in 80+ countries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270448,"accession_number":"0001437749-23-027935","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Mesa Labs increases revolving credit facility to $125M from $75M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Credit agreement amended on Oct 5, 2023; revolving commitment raised to $125.0M from $75.0M.","No amounts drawn under the credit agreement as of the filing date.","Proceeds may be used for refinancing, working capital, and general corporate purposes, including permitted acquisitions.","Certain administrative amendments made to accommodate business changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287399,"accession_number":"0001437749-23-024877","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2023-08-30T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Mesa Labs dismisses Plante & Moran, appoints RSM as auditor; discloses two material weaknesses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed Plante & Moran and engaged RSM US, LLP effective August 28, 2023.","No disagreements with Plante & Moran on accounting principles or audit scope during FY2022-FY2023.","Two material weaknesses in internal controls as of March 31, 2023: Belyntic acquisition valuation (remediated) and goodwill impairment assessments (not fully remediated).","Plante & Moran's audit reports for FY2022 and FY2023 contained no adverse opinion or qualification.","Change triggered by Plante & Moran evaluating its SEC audit practice in the company's primary industry."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287398,"accession_number":"0001437749-23-024684","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2023-08-25T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Mesa Labs shareholders approve governance amendments, reject ESG emissions proposal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All director nominees elected: Sullivan, Ladiwala, Alltoft, Hall, Tripeny, Owens.","Amended articles to remove specific purposes and expand director exculpation approved.","Say-on-pay approved with 4.4M for vs 189K against.","Amendment to 2021 Equity Incentive Plan approved (4.6M for).","Shareholder proposal for GHG Scope 1-3 reporting rejected: 3.3M against, 1.3M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287397,"accession_number":"0001437749-23-021752","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs 1Q24 revenue $50.6M (+0.4%), net loss $(0.10)/share, AOI up 46% to $9.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $50.6M, +0.4% YoY; core organic growth 2.0% (ex-currency/COVID).","Operating loss narrowed 85.5% to $(0.7M); net loss $(0.5M) or $(0.10)/share.","Non-GAAP AOI excluding unusual items rose 46.2% to $9.5M (18.8% of revenue).","Divisions: Calibration +12.5% core organic, Sterilization +7.2%, Clinical Genomics -4.4%, Biopharma -6.6%.","Headwinds: slowing capital equipment, Sema4 loss, currency; cost cuts aiding profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":50645000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307543,"accession_number":"0001437749-23-015770","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q4 revenue down 5.6%, AOI down 21%; FY net income down 50% to $0.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenues $55.6M, -5.6% YoY; net income $0.6M ($0.11 diluted EPS) vs net loss $1.8M prior year.","FY23 revenues $219.1M (+18.8%); core organic growth 5.2%; net income $0.9M ($0.17) -50.3% YoY.","AOI ex-unusual items Q4 $10.7M (-21.1% YoY); FY23 $45.8M (-1.7% YoY).","Clinical Genomics revenues -15.8% organic; Sema4 closure headwind ~$8.2M annually.","Management guides conservatively for FY24; sees soft CAPEX orders, expects currency headwinds to abate."],"consensus_eps_estimate":null,"consensus_eps_actual":0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":219080000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307542,"accession_number":"0001437749-23-012905","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director John B. Schmieder not standing for re-election at 2023 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John B. Schmieder, director since 2015, will not stand for re-election at 2023 annual meeting.","Currently Chair of Nominating and Governance Committee and member of Audit Committee.","Decision not related to any disagreement with Mesa's operations, policies, or practices.","He will continue to serve as director through the date of the annual meeting.","Committee assignments to be determined prior to his departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326556,"accession_number":"0001437749-23-006281","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Mesa Labs says SVB closure impact immaterial; excess deposits <$500K vs $26.1M cash","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Deposit accounts at SVB above FDIC-insured limits are less than $500,000.","Total cash and equivalents were $26.1M as of Dec 31, 2022, held at multiple large financial institutions.","FDIC stated depositors will have access to all funds starting March 13, 2023.","Company believes existing cash and cash flow sufficient for working capital and capex needs.","No other material positions or relationships with SVB."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326555,"accession_number":"0001437749-23-002547","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2023-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q3 revenue -1% to $54.3M; core organic growth 4.6%; net income up 122%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenues $54,287K, down 1% YoY; organic revenue decline 2.1% due to currency and other headwinds.","Net income $451K ($0.08 diluted EPS) vs $203K in prior year; increase of 122%.","Non-GAAP AOI excluding unusual items $12,856K (24% of revenue), down 7% YoY.","Clinical Genomics revenues $15,585K, down 10% organic; core organic growth 3.3% ex-Sema4 would be 19%.","SDC core organic growth 21.1%; Calibration Solutions impacted by supply chain constraints."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":163489000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326554,"accession_number":"0001437749-23-000281","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K/A","filed_at":"2023-01-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Mesa Labs amends 8-K with say-on-pay frequency vote results; board opts for annual vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-binding advisory vote on say-on-pay frequency: 4,330,300 for every 1 year, 6,130 for 2 years, 43,642 for 3 years, 2,849 abstain, 296,490 broker non-votes.","Board determines company will hold annual advisory vote on executive compensation until next required frequency vote.","Initial 8-K filed Aug 26, 2022 omitted say-on-pay frequency vote results; this amendment corrects."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344274,"accession_number":"0001437749-22-027857","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2022-11-21T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Mesa Labs loses key customer Sema4; orders to drop starting Q3 FY2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sema4 exiting reproductive health screening; will significantly reduce consumables orders starting Q3 FY2023.","Without Sema4, Clinical Genomics ex-COVID revenues would have been ~$56.3M vs $64.5M over prior 12 months.","Sema4 products generated significantly higher gross profit percentage than overall Clinical Genomics business.","Mesa has no other material revenues for expanded carrier screening with other customers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344273,"accession_number":"0001437749-22-026017","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2022-11-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Mesa Labs re-establishes Lead Independent Director role, appoints Shiraz Ladiwala","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board re-created position of Lead Independent Director effective November 3, 2022.","Current board member Shiraz Ladiwala appointed to the role; he has served since Oct 2021.","Appointment is part of ongoing corporate governance enhancements at Mesa.","Ladiwala will receive compensation under the Board's director compensation policies.","CEO Gary Owens stated the role will improve oversight and governance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344271,"accession_number":"0001437749-22-025993","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K/A","filed_at":"2022-11-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Mesa Labs appoints Tony Tripeny to Audit Committee effective Nov 2, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board appointed Tony Tripeny to Audit Committee, effective November 2, 2022.","Tripeny had been elected to Board on June 23, 2022; prior 8-K noted likely committee assignment.","Board determined Tripeny satisfies Nasdaq and SEC requirements for Audit Committee service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344272,"accession_number":"0001437749-22-025648","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q2 revenue up 64% but GAAP EPS down 65%; non-GAAP AOI up 55%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $58.7M (+64% YoY); organic growth 12% (18% constant currency). Net income $1.3M (-65%), diluted EPS $0.24.","GAAP operating income $4.0M (-5%); non-GAAP AOI $15.5M (+55%), $2.88 per diluted share.","Segments: Clinical Genomics $18.4M (+27% seq), Sterilization $17.0M (+21% org), Biopharma $12.1M (+15% org), Calibration $11.2M flat.","H1 revenue $109.2M (+54%); GAAP operating loss $0.6M, net loss $0.1M; non-GAAP AOI $21.6M (+13%)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":109202000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":360769,"accession_number":"0001437749-22-021400","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2022-08-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Mesa Labs shareholders reject advisory vote on executive compensation at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders elected all seven director nominees; John B. Schmieder received 3,938,677 for and 444,244 withheld.","Advisory vote on executive compensation was not approved: 1,039,445 for, 3,046,595 against, 296,881 abstain.","Ratification of Plante & Moran as independent auditor for FY2023 approved: 4,603,003 for, 73,303 against, 3,105 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":360768,"accession_number":"0001437749-22-018743","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q1: revenue up 44% but net loss of $1.4M; organic growth slows to 3%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS loss of ($0.27) vs prior-year EPS of $0.38; net loss of ($1.438M) from $1.995M income.","Revenue $50.5M (+44% total, +3% organic); non-GAAP adjusted OI $6.158M (-33%) or $1.17/share.","Clinical Genomics (29% rev) hit by China lockdowns; Sterilization & Disinfection down 2%.","Biopharma Development grew 24%; Calibration Solutions fell 6% on supply chain shortages.","Unusual items: $356K in Agena integration costs; management cites FX, labor, and material headwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":50453000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379888,"accession_number":"0001437749-22-015936","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2022-06-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Mesa Labs appoints former Corning CFO Tony Tripeny to board, expanding to 8 members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tony Tripeny appointed to Mesa Labs board effective June 23, 2022; board size increased from 7 to 8.","Tripeny retired May 2, 2022 as EVP and CFO of Corning after a 36-year career; likely to join Audit Committee.","Six of eight directors are independent; Tripeny deemed independent under Nasdaq and SEC rules.","No reportable related-party transactions with Tripeny; he will receive standard outside director compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379887,"accession_number":"0001437749-22-013842","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2022-05-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs reports Q4 GAAP operating loss of $110k; adjusted op income ex-unusual items up 31%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP operating loss of $110k vs income of $4.3M a year ago; net loss $1.78M (-$0.34 diluted EPS).","Non-GAAP adjusted operating income (AOI) rose 11% to $11.65M; AOI ex-unusual items up 31% to $13.57M.","Total revenues grew 55% in Q4 to $58.9M, organic +12%; FY revenues up 38% to $184.3M, organic +13%.","Clinical Genomics segment revenue $16.4M including $1.4M COVID; ex-COVID below plan, China lockdowns expected to impact Q1.","FY23 guidance cautious: lower organic growth expected due to inflation, war in Europe, and Asia pandemic resurgence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379886,"accession_number":"0001437749-22-008628","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2022-04-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Mesa Laboratories SVP Greg DiNoia to depart June 30, 2022; severance and retention bonus disclosed.","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Greg DiNoia, SVP of Commercial Operations, will leave Mesa Labs on June 30, 2022.","Severance: one times base salary plus target bonus, prorated annual bonus, additional year incentive comp, 24 months COBRA.","Equity acceleration: all awards with >3yr vest schedule vested; 2024 RSUs/options accelerated; performance shares at higher of actual/target.","Retention bonus of $90,000 for transition through June 30, plus pro-rata Q2 2022 bonus at 100% attainment.","Company thanks DiNoia for his service and will require a release of claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379885,"accession_number":"0001437749-22-008332","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2022-04-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Mesa Labs enters $150M at-the-market equity offering agreement with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement allows sale of up to $150M in common stock through Jefferies as sales agent.","Jefferies to receive 3.0% commission on gross proceeds from each sale.","Sales may be made at market prices; no obligation to sell any shares.","Offering made under effective S-3 registration statement filed April 5, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":398046,"accession_number":"0001437749-22-007720","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2022-03-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Mesa files Agena financials post-acquisition; revises segment reporting structure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agena's revenue for nine months ended Sep 30, 2021: $58.4M, up 45% YoY; net income of $12.8M vs loss of $0.38M.","Mesa recast FY2021 segment data into four segments: Sterilization/Disinfection, Clinical Genomics (Agena), Biopharma Development, Calibration Solutions.","Pro forma combined statement for nine months ended Dec 31, 2021 filed; acquisition closed Oct 20, 2021.","Agena's cash and equivalents fell to $3.7M from $16.1M at Dec 31, 2020; debt repaid $22.5M during period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":398045,"accession_number":"0001437749-22-002289","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2022-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q3 revenue up 60% to $54.7M; GAAP operating loss $2.5M on Agena acquisition costs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $54.7M (+60% YoY); organic revenue growth 12%.","GAAP operating loss $2.5M; net loss $0.39/diluted share.","Non-GAAP adjusted op. income $7.1M; excl. unusual items $13.8M (+73%).","Biopharma division organic growth 46%; Calibration Solutions revenue fell 6%.","Acquired Agena Bioscience in Oct 2021; cash reserves fell from $264M to $52M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":125456000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":417037,"accession_number":"0001437749-21-029173","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2021-12-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Mesa Labs announces new segment reporting structure effective Q3 FY2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four new segments: Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, Calibration Solutions.","Clinical Genomics segment consists of recently acquired Agena Bioscience business.","Calibration Solutions combines former Instruments and Continuous Monitoring segments.","Over 90% of future revenues expected from pharma, medical device, and healthcare verticals.","Change reflects management's focus on higher-growth Life Sciences Tools applications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":417033,"accession_number":"0001437749-21-029096","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K/A","filed_at":"2021-12-22T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Mesa Labs files Agena acquisition financials; Agena's 2020 revenue $68.5M, net income $5.1M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Agena audited 2020 revenue $68.5M (systems $17.9M, consumables $44.5M, services $6.0M).","Agena net income $5.1M in 2020 vs. net loss $4.8M in 2019.","Agena total assets $58.4M, total liabilities $44.0M, stockholders' deficit $38.0M at Dec 31, 2020.","Mesa's unaudited pro forma combined balance sheet as of Sep 30, 2021 and P&L for year ended Mar 31, 2021 included.","Series A redeemable convertible preferred stock of $52.4M and preferred stock warrant liability of $2.9M exist."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":417036,"accession_number":"0001437749-21-025178","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mesa Labs Q2 FY22 revenue $35.84M (+12%), net income up 39% to $3.72M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $35.84M (+12% YoY); operating income $4.20M (-6%); net income $3.72M (+39%); diluted EPS $0.70 vs $0.51.","Sterilization & Disinfection Control organic growth 21%; Biopharma Development organic growth 16%; Continuous Monitoring revenue record (+18%).","Instrument division revenue down 8% due to component supply and labor constraints; backlog increased.","Non-GAAP adjusted operating income $9.997M (flat YoY); adjusted diluted EPS $1.87 vs $1.91.","Completed acquisition of Agena Bioscience on Oct 20, 2021, adding Clinical Genomics capabilities."],"consensus_eps_estimate":null,"consensus_eps_actual":1.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":70760000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":417035,"accession_number":"0001437749-21-024583","cik":724004,"company_name":"MESA LABORATORIES INC /CO/","ticker":"MLAB","form_type":"8-K","filed_at":"2021-10-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Mesa Labs appoints Shiraz Ladiwala to board, grants CEO special PSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shiraz Ladiwala appointed to Board, effective Oct 28, 2021; board expands from 7 to 8 members.","Ladiwala retired from Thermo Fisher Scientific as SVP, Business Transformation Projects.","CEO Gary Owens granted special performance stock units with target of 40,000 shares.","PSU vesting tied to cumulative GAAP revenue (30% weight) and adjusted operating income (70%) over 3 years through Mar 31, 2024.","No shares vest if performance below 80% of target; vesting occurs in three annual tranches starting Oct 27, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":501653027.9174907,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-10-29T23:59:59+00:00|417035"}